Talbird SE, Brogan AJ, Winiarski AP. Oseltamivir for influenza postexposure prophylaxis: economic evaluation for children aged 1-12 years in the U.S. Am J Prev Med. 2009 Nov 1;37(5):381-8.
Smets E, Stoll M, Hill A, Soorapanth S, Donatz V, Brogan AJ. Comparative cost-efficacy analysis of darunavir/r and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in Germany. Poster presented at the 12th European AIDS Conference/EACS; November 2009.
Kauf T, Davis KL, Earnshaw S, Davis EA, Watson ME. Spillover adherence effects of fixed-dose combination HIV therapy. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 28, 2009. [abstract] Value Health. 2009 Oct; 12(7):A430.
Smets E, Soorapanth S, Brogan AJ, Mrus J. Cost-efficacy analysis of darunavir/r vs. lopinavir/r as a first-line HIV treatment in the United States. Poster presented at the 47th Annual Meeting of the Infectious Diseases Society of America; October 2009.
Menzin J, Meyers JL, Friedman M, Perfect JR, Langston AA, Danna RP, Papadopoulos G. Mortality, length of hospitalization, and costs associated with invasive fungal infections in high risk patients. Am J Health Syst Pharm. 2009 Oct;66(19):1711-7. doi: 10.2146/ajhp080325.
Bapat BS, Bell TJ, Candrilli SD. Estimates of the indirect burden of invasive meningococcal disease: insight from public health officials. Poster presented at the 47th Annual Meeting of the Infectious Diseases Society of America; October 2009.
Knoll S, Jochum D, Talbird SE. Cost-utility analysis of pneumococcal conjugate vaccines in Germany. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France. [abstract] Value Health. 2009 Oct; 12(7):A429.
Whillans F, Kwan H, Strutton DR, Earnshaw SR, Farkouh RA. Cost-effectiveness of 13-valent and 10-valent pneumococcal conjugate vaccination relative to 7-valent pneumococcal conjugate vaccination in Canada. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France. [abstract] Value Health. 2009 Oct; 12(7):A425.
Lasry A, Sansom S, Hicks KA, Uzunangelov VJ. A model for allocating HIV prevention resources in the United States. Poster presented at the National HIV Prevention Conference; August 2009.
Poulos C, Levin C, Hoang V, Yang J, Nguyen D. Mothers' and fathers' private demand for HPV vaccines in Viet Nam. Poster presented at the 7th World Congress on Health Economics: Harmonizing Health and Economics; July 2009.
Bischof M, Brogan AJ, Talbird SE, Cavassini M, Bernasconi E, Furrer H. Cost-effectiveness of the first-line antiretroviral backbone therapies in combination with efavirenz in HIV-infected patients in Switzerland. Poster presented at the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 2009. Cape Town, South Africa.
Strutton DR, Kuchenbecker U, Earnshaw SR, Farkouh RA. Impact of 13-valent pneumococcal conjugate vaccination on costs and outcomes in Germany and the United States. Poster presented at the 27th Annual Meeting of the European Society for Paediatric Infectious Diseases; June 2009.
Stoykova B, Strutton DR, Earnshaw SR, Farkouh RA. Cost-effectiveness of 13-valent pneumococcal conjugate vaccination relative to 7-valent pneumococcal conjugate vaccination in the United Kingdom (UK). Poster presented at the 27th Annual Meeting of the European Society for Paediatric Infectious Diseases; June 2009. Brussels, Belgium.
Soorapanth S, Brogan AJ, Mrus J, Smets E. Comparative cost-efficacy analysis of darunavir/r for first-line treatment of HIV infection in the US. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research 14th Annual International Meeting; May 2009. [abstract] Value Health. 12(3):A112.
Rivera R, Strutton D, Hwang S, Earnshaw SR, Farkouh RA. Cost-effectiveness of 13-valent pneumococcal conjugate vaccination versus 7-valent pneumococcoal conjugate vaccination in Mexico. Poster presented at el Pediátrica XIII Congreso Latinoamericano de Infectología Pediátrica; May 2009.
Hernandez JD, Strutton D, Hwang S, Earnshaw SR, Farkouh RA. Impact of 13-valent pneumococcal conjugate vaccination compared to 7-valent pneumococcal conjugate vaccination in Colombia. Poster presented at La Sociedad Latinoamericana de Infectología Pediátrica XIII Congreso Latinoamericano de Infectología; May 2009.
Brogan AJ, Everhard F, Talbird SE, Hutt E. Cost-effectiveness of tenofovir/emtricitabine in treatment naïve adults with HIV infection in the United States. Poster presented at the 21st Annual Meeting and Showcase of the American Managed Care Pharmacy; April 2009.
Lauria DT, Maskery B, Poulos C, Whittington D. An optimization model for reducing typhoid cases in developing countries without increasing public spending. Vaccine. 2009 Mar 4;27(10):1609-21.
Talbird SE, Brogan AJ, Winiarski AP, Sander B. Cost-effectiveness of treating influenzalike illness with oseltamivir in the United States. Am J Health Syst Pharm. 2009 Mar 1;66(5):469-80.
Whittington D, Sur D, Cook J, Chatterjee S, Maskery B, Lahiri M, Poulos C, Boral S, Nyamete A, Deen J, Ochiai L, Bhattacharya SK. Rethinking cholera and typhoid vaccination policies for the poor: private demand in Kolkata, India. World Dev. 2009 Feb 1;37(2):399-409.
Mast C, DeMuro-Mercon CJ, Kelly C, Floyd LE, Walter E. The impact of rotavirus gastroenteritis on the family. BMC Pediatr. 2009 Feb;9(11).
Brogan AJ, Soorapanth S, Donatz V, Hill A, Smets E. Comparative cost-efficacy analysis of darunavir/r and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in Germany. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 28, 2009. Paris, France. [abstract] Value Health. 2009; 12(7):A426.
Lanes SF, Rothman KJ. Tampon absorbency, composition and oxygen content and risk of toxic shock syndrome. J Clin Epidemiol. 1990 Jan 1;43(12):1379-85.